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Introduction
Fragility fractures of the proximal femur are a sig-
nificant social problem, considering the high fre-
quency among senior citizens and the mortality
rate related to such fractures(1,2). They are typical of
the age group for whom healing is negatively influ-
enced by variations in bone structure and healing
processes. Surgical treatment includes the use of
prostheses or other surgical devices (screws, nails)
chosen by the surgeon on the basis of the charac-
teristics of the specific fracture and the patient’s
general clinical condition. Medical treatment also
helps healing by promoting the formation of new
bone and by reducing bone re-absorption, thereby
stimulating bone healing and decreasing the risk of
new fractures. Nowadays treatment is attempted as
soon as possible to reduce the risk of complications
related to delayed healing and prolonged hospital-
ization. The goal of this study is to clarify the
physiological steps and processes of healing of
fractures of the proximal femur and possible treat-
ments to accelerate healing.
Generality
There are usually four healing phases follow-
ing a traumatic bone fracture(3,4,5).
• Inflammatory phase (1-7 days): immediate-
ly after the trauma the surfaces of the fracture
bleed and a hematoma forms as a result of the rup-
ture of the intra-bone vessels, periosteal and the
surrounding center. The bone near the margins of
the fracture necrotizes, and the coagulate is infil-
trated by leukocytes, macrophages, mastocytes,
and fibroblasts to remove the necrotic bone.
• Fibrous callus phase (2-3 weeks): the coag-
ulate hardens due to the presence of collagen fiber
and vasal elements; there is a proliferation of bone
progenitor cells (preosteocytes), and osteoblasts of
the cambial layer of the periosteum and the endos-
teum; osteoblasts and condroblasts of mesenchy-
mal origin also appear. There is also the formation
of fibrous callus composed of osteoid, cartilage
and collagen (hardening of the hematoma and for-
mation of osteogenic and condrogenic tissue).
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• Osseous callus phase (1-4 months): miner-
alization of the osteoid and cartilage of the external
fibrous callus, periostal, and endostal, through their
transformation in primitive bone. Hence there is a
re-absorption of dead bone and the formation of
new bone tissue.
• Remodeling phase may last a few months to
years. The activity of osteoblasts and osteoclasts
slowly transforms primitively formed bone into
mature lamellar bone, having true haversian sys-
tems. This phase leads to the consolidation of the
fracture(6,7).
Consolidation of the fragility fracture
The consolidation of a fracture under physio-
logical conditions normally occurs within a certain
period called normal consolidation time and which
is from 15-20 days (e.g. greenwood fracture of a
child’s clavicle), to a maximum of 5-6 months (e.g.
middle-third or lower tibia in the adult), according
to the three variables that influence healing time:
skeletal location, type of fracture, and patient’s
age(8). The physiological healing processes are
modified in some bone pathologies, especially
osteoporosis. Under physiological conditions the
process of bone remodeling where the bone is con-
tinually formed as a result of the osteoblasts,
equals the bone that is gradually reabsorbed by the
osteoclasts.
Under pathological conditions, in contrast, the
action of the osteoclasts is predominant over the
osteoblasts with the consequent increase in the re-
absorption of bone, a general increase in bone
turnover, and deleterious effects both on the quan-
tity and quality of bone, leading to the extreme
condition of fragile fracture(9,10). Structural bone
variations which we previously described negative-
ly influence the healing of these fractures, especial-
ly in primitive osteoporosis(11).
Compromise of the healing process in primitive
osteoporosis
In post-menopausal osteoporosis the estrogen
deficit is responsible for an increase of the activity
in osteoclasts, and hence an increase in bone
turnover, which negatively influences all phases of
fracture healing, especially the final phases of min-
eralization and remodeling(12).
In senile osteoporosis there are several prob-
lems related to skeletal fragility that can negatively
influence fracture healing:
• Cellular senescence, in which the mes-
enchymal cells no longer mature due to the
reduced expression of the RUNX-2/, Cbfal and
Osx genes(13). There is also an increase in differenti-
ation of the multipotent (MSCs) cell progenitor in
the adipose tissue and a reduction in osteogenesis.  
• Nutritional deficiency and malabsorption
of nutrients and important hormones for bone
metabolism (vitamin D, phosphorus, potassium,
magnesium, calcium, vitamin K, vitamin B, pro-
teins, etc.). Specifically, the deficiency in minerals
and vitamin D cause reduced mineralization of the
callus bone and hence the bone neoformation; vita-
min K deficiency causes reduced enzyme activa-
tion of osteocalcin, which decreases the ability to
bind with the hydroxyapatite crystals; the deficien-
cy in B vitamins (B6 and B12) may alter the three-
dimensional conformation of the bone matrix; pro-
tein deficiency contributes to sarcopenia in elderly
patients(14). 
• Vitamin D deficiency is very common in
elderly patients due to malabsorption and/or
reduced exposure to sunlight, which alters the
structure and mineralization of the bone callus. In
addition, a failure of vitamin D to bind with its
receptor (VDR) may lead to sarcopenia(15,16,17).
• In sarcopenia there is a reduction in the
number of muscle fibers, which is responsible for
the reduced contribution in muscle stem cells with
osteogenic capacity(18). 
• Chronic systemic inflammation is directly
correlated with bone metabolism. Post-menopausal
estrogen deficiency and the increase in adipose tis-
sue (liver, marrow, muscles) cause a massive pro-
duction in pro-inflammatory cytokines, some of
which (IL-1, IL-6) may increase osteoclastic activ-
ity, while others (IL-7, TNF-α) cause a reduction
in osteoblastic activity(19,20).
There are also numerous metabolic changes
that may negatively influence the structure and
composition of callus in elderly patients.
• Disorganized positioning of the collagen
fiber
• Decreased maturation of the cartilaginous
callus 
• Thin trabecular bone neoformation with
extensive microporosity.
All of these factors result in an alteration of
mechanical properties of bone hence in a pro-
longed fracture healing. 
Fracture of the femur neck
The elderly population has a high frequency of
femur neck fractures, so it is a significant public
health problem, both in terms of social costs (quality
of life declines after fractures, life expectancy is sig-
nificantly shorter), and economic costs(21). Fractures
of the proximal femur are classified as medial or lat-
eral on the basis of an anatomical distinction
between the intercurrent relation of the level of the
fracture and the distal insertion of the articular cap-
sule of the hip. Medial fractures are intra-capsular
and are divided into sub-capital (Fig. 1a) or mid-cer-
vical (Fig. 1b). They are subdivided as Garden type
I, II, III, or IV according to the degree of severity of
separation and a worse prognosis (Fig. 2a,b,c,d).
Lateral fractures are extra-capsular and are divided
into basi cervical, petrochanteric and sub-
trochanteric fractures (Fig. 3c,d,e).
The treatment of femur neck fractures con-
sists of the attempts to restore the patient’s func-
tional autonomy, and prevent other general compli-
cations that interfere with healing and recovery.
Effective surgery must take some fundamental fac-
tors into account to achieve good healing or ade-
quate reduction of the fracture, choosing an appro-
priate surgical devices to improve the stability of
the synthesis. Therapeutic alternatives depend on
the type of fracture, which may require a prosthesis
or osteosynthesis.
Medial fractures have a poorer prognosis due
to the vascularization of the head and the neck, and
the consolidation and vitality of the head, so a
prosthesis is more often necessary (Fig. 4). Lateral
fractures have a better prognosis because they
don’t involve the articular capsula and its arterial
circulation, so healing is possible through adequate
reduction and synthesis. The choice depends on the
characteristics of the fracture and the patient’s gen-
eral condition. Cannula screws and intramedullary
nails are less invasive because doesn’t cause the
opening of the fracture (Fig. 5); instead screw-plate
systems require more surgical exposure.
Sometimes the implants causes a modest seal
of the bone, due to the presence of a broad diaphy-
seal canal, or a cavum profile in the epiphysial
region. So it is important to ensure a good interface
between bone and implants to reduce the risk of
osteosynthesis failure. In such cases bone tissue
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Fig 1: Medial fracture: a) subcapital, b) midcervical.
Fig 2 a-b-c-d: Garden classification.
Type 3
Type 1 Type 2
Type 4
Fig 3: Lateral fracture: c) basicervical, d) pertrochante-
ric, e) subtrochanteric.
Fig 4 a-b: Medial fracture a) treated with bipolar hip
prosthesis b).
should be stimulated via autologue or allogenic
bone transplant (demineralized bone matrice, etc.),
or by using osteo-inducing factors (BMPs, PRP,
MSCs, etc.).
In addition, the stability of the implants can
be improved by using augmentation factors
(hydroxyapatite, calcium triphosphate, calcium
phosphate cement)(23,24). The goal of osteosynthesis
in lateral fractures of the femur is to achieve a
quick recovery of mobility even before the com-
plete bone healing and the bearing is as a stimulus
for bone callus formation(25). Alongside surgical
treatment of fragility fractures it is also impor-
tant(22). There used of drugs like bisphosphonates,
parathormone (PTH 1-34), strontium ranelate, and
more recently biological drugs (monoclonal anti-
bodies); these drugs modify the processes of bone
turnover on several levels:
• PTH (1-34) stimulates osteoblastic activity,
which causes the adding of new bone on the tra-
becular and cortical surfaces(26),
• The bisphosphonates (alendronate, rise-
dronate, clodronate) inhibit the action of the osteo-
clasts and therefore the re-absorption of bone, even
though recent studies have evaluated the positive
effects of the drug on the fracture healing process,
and on the prosthesis osseointegration if used for a
brief time in the immediate postoperative period(27,28);
• strontium ranelate is a dual action bone
agent (DABA) as inhibits the production of osteo-
clasts and therefore the destruction of bone and at
the same time stimulates the differentiation of
osteoblasts and the production of new bone(29);
• biological therapy consists of the monoclon-
al antibodies of human origin (Denosumab) that
inhibit the osteoclast activator (RANKL), thereby
preventing the loss of bone mass(30);
Considering these factors it is clear that med-
ical treatment is an important part of accelerating
the healing of fractures of the proximal femur, in
that the drugs improve the quality of the bone, cul-
tivating osseointegration and the seal of the
implants as well as good healing of the fracture.
Conclusions
The orthopedic surgeon has two challenges
when treating a patient with a fragility fracture:
choosing the most appropriate therapy for the actu-
al fracture, and identifying the particular pathology
of the fracture to prevent new fractures by using
the best tools available against osteoporosis. The
choice of surgical technique depends not only on
the characteristics of the fracture, but also on the
individual patient’s factors such as age and general
health. The preference should be for the least inva-
sive techniques possible, for less risk of complica-
tions and the shortest surgical operations.
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